Plain-English translation of NCT06823960 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study looking at how zanubrutinib performs in patients with marginal zone lymphoma—a rare type of blood cancer that has returned or stopped responding to previous treatments. Researchers in Italy are gathering information from patients who already received this medication through a special access program to learn whether the medication works well and is safe in everyday practice.
Marginal zone lymphoma is rare, and this medication is relatively new for treating it. By collecting data from patients who have already been treated with this medication, researchers hope to gather early evidence about how effective and safe the treatment is, which will help plan larger studies in the future.
You likely qualify if…
You likely don't qualify if…
As a participant, researchers will gather your medical information from the time you started the medication until six months after you finished treatment. This is not an active treatment trial—instead, doctors will review your existing medical records and health data to track how well the medication worked for you and what side effects you experienced. You will not receive the medication as part of this study; rather, your past experience with it will be documented.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Italy